Vitamin D supplementation is associated with disease activity in system lupus erythematosus patients

The 1st International Electronic Conference on Nutrients - Nutritional and Microbiota Effects on Chronic Diseas

María Correa-Rodríguez, Gabriela Pocovi-Gerardino, Irene Medina-Martínez, Sara Del Olmo-Romero, Norberto Ortego-Centeno, Blanca Rueda-Medina

INTRODUCTION



Fava, A.; Petri, M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 2019, 96, 1–13.

Systemic **AUTOIMMUNE** disease characterized by the presence of autoantibodies directed against nuclear

Heterogenous clinical manifestation including rash, arthritis, fatigue, nephritis, neurological problems, anemia and thrombocytopenia.







OBJECTIVE

Investigate the relationship between the dietary intake vitamin D and supplementa of vitamin D and SLE diseas cohort of patients with SLE.

iship
take of
nentation
lisease in a





INMUNOLOGICAL

ENDOCRINAL

ENVIROMENTAL

Rekvig, O. P. Systemic lupus erythematosus: Definitions, contexts, conflicts, enigmas. Front Immunol 2018, 9, 1, doi:10.3389/fimmu.2018.00387.

The AETIOLOGY of SLE is unknown. It has proposed that multiple factors might play a main role in development and activity





VITAMIN D



Essential in phosphorus-calcium metabolism and it has immunosupressive properties

> Therapeutic option in **AUTOINMMUNE** diseases





Vitamin D intake was found to be associated with decreased risk of other autoimmune diseases such as multiple sclerosis.

45, 217-226.

aggravation. Autoimmun Highlights 2018, 9, 1–10, rheumatoid arthritis in women. Ann Rheum Dis 2008, 67, 530–535 65.



Yang, C. Y.; Leung, P. S. C.; Adamopoulos, I. E.; Gershwin, M. E. The implication of vitamin D and autoimmunity: A comprehensive review. Clin Rev Allergy Immunol 2013,

Hassanalilou, T.; Khalili, L.; Ghavamzadeh, S.; Shokri, A.; Payahoo, L.; Bishak, Y. K. Role of vitamin D deficiency in systemic lupus erythematosus incidence and

Costenbader, K. H.; Feskanich, D.; Holmes, M.; Karlson, E. W.; Benito-Garcia, E. Vitamin D intake and risks of systemic lupus erythematosus and Munger, K. L.; Zhang, S. M.; O'Reilly, E.; Hernán, M. A.; Olek, M. J.; Willett, W. C.; Ascherio, A. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62, 60-







Cross-sectional study

258 patients SLE Andalusian region of Spain



All statistical analyses were conducted using the SPPS Statistics version 21.0 software

METHODS

INCLUSION CRITERIA



SLE revised criteria

American College of Rheumatology (ACR)

.

Systemic Lupus Erythematosus International Collaborating Clinics Group (SLICC) criteria



EXCLUSION CRITERIA



Kidney involvement

Active infections

Pregnancy

Cerebrovascular disease, ischemic heart disease

Major trauma or surgery in the previous six months

Presence of other autoimmune and/or chronic diseases not related with SLE

VARIABLES

CARACTERISTICS

Gender, age, energy (kcal), vitamin D intake

CLINICAL DATA

Time since diagnosis (years), number of complications, SLEDAI score, SDI score



hsCRP, Hcy, Anti-dsDNA, complement C3 and C4 levels.

METHODS

LABORATORY MARKERS

MEDICATION USED

Vitamin D supplementation, antimalarial use, immunosuppressor use, corticoid use

Table 1. Descriptive of the main characteristics the study population

Characteristics	Total (n=193)		
Female	248 (90.5)		
Age (years)	46.99±12.89		
Energy (kcal)	1775.03 ± 507.69		
Vitamin D intake (µg)	2.08 ± 2.94		
Clinical data			
Time since diagnosis (years)	9.11±6.64		
Number of complications	3.38±1.34		
SLEDAI ^a score	2.65 ± 2.68		
SDI score	0.97±1.23		
Laboratory markers			
hsCRP (mg/dL)	3.17±4.81		
Hcy (µmol/L)	12.48±7.45		
Anti-dsDNA (IU/mL)	18.37±37.09		
Complement C3 level (mg/dL)	109.17±28.25		
Complement C4 level (mg/dL)	22.81±13.56		
Medication used			
Vitamin D supplementation	156 (57.1%)		
Antimalarial use	217 (79.5)		
Immunosuppressor use	102 (37.4)		
Corticoid use	108 (39.6)		





RESULTS

Table 2. Beta estimates and confidence intervals fo e association between vitamin D intake, vitamin D supplementation and clinical disease activity parameters in SLE patients

	Vitamin D intake (µg)	Vitamin D su			
Clinical parameters	β (95% CI)	p value	Yes (n=156)	No (n=117)	P value
Number of complications	0.004 (-0.049, 0.056)	0.895	3.53±1.44	3.17±1.18	0.922
SLEDAI score	0.015 (-0.092, 0.121)	0.784	2.68 ± 2.85	2.57 ± 2.40	0.229
SDI score	0.012 (-0.036, 0.060)	0.623	1.19 ± 1.35	0.66 ± 0.96	0.123
hsCRP (mg/dL)	-0.108 (-0.301, 0.086)	0.274	3.76 ± 5.54	2.29 ± 3.37	0.238
Hcy (µmol/L)	0.339 (-0.052. 0.731)	0.089	13.66 ± 9.50	11.05 ± 3.18	0.016
Anti-dsDNA (IU/mL)	0.493 (-1.013, 1.999)	0.520	21.33 ± 43.41	14.54 ± 26.12	0.938
Complement C3 level (mg/dL)	-0.759 (-1.869, 0.351)	0.180	110.28 ± 30.93	107.38 ± 24.18	0.018
Complement C4 level (mg/dL)	-0.433 (-1.128.0.261)	0.220	22.53 ± 12.94	23.16 ± 21.41	0.894



DISCUSSION

Patients taking vitamin D supplements had significantly higher levels of complement 3. Unexpectedly, we also found that patients with SLE who took vitamin D supplements had significantly higher Hcy levels.

Well-characterised cohort of population with SLE, including patients in a early-stage of the disease and excluding any with lupus severe complications or affected by other autoimmune diseases.



In contrast to our results, Mellor Pita et al reported no association between vitamin D supplement intake and SLErelated factors including Hcy in 46 females with SLE. Constenbader et al conclude that vitamin D intake was not associated with risk od SLE in a large prospective cohort of women.



LIMITATIONS



Use of the 24 hour diet recall technique because it is prone to under-reporting and relies on participant memory.



Cross-sectional study, was subject to the limitations inherent to this type of design.

CONCLUSION





Patients taking vitamin D supplements had significantly higher levels of complement 3, supporting the potential effect of supplementation of vitamin D on the activity of SLE

The dietary intake of vitamin D are not associated with clinical and laboratory variables in women with SLE

Vitamin D supplementation is associated with disease activity in system lupus erythematosus patients

The 1st International Electronic Conference on Nutrients - Nutritional and Microbiota Effects on Chronic Diseas

María Correa-Rodríguez, Gabriela Pocovi-Gerardino, Irene Medina-Martínez, Sara Del Olmo-Romero, Norberto Ortego-Centeno, Blanca Rueda-Medina